Maximon, Marcuard Heritage, and GenTwo have announced the launch of a new longevity-related investment opportunity. Their proposal allows professional investors to get access to Maximon’s portfolio of longevity companies via an actively managed certificate (AMC).
According to Maximon, there have been many requests to launch an AMC focused on longevity. Therefore, Marcuard Heritage, a top Swiss wealth manager, supported by GenTwo, a Swiss fintech company, made it happen.
“Together with AI, longevity is likely the biggest – and most rewarding – investment opportunity in the 21st century. We are pleased that Marcuard Heritage now also offers access to professional investors with the AMC structure.” – Tobias Reichmuth, Founding Partner of Maximon.
What are actively managed certificates?
These are financial products that allow investors to benefit from portfolios managed by experienced professionals. AMCs don’t pool assets like traditional funds. Instead, they offer exposure to asset performance by issuing debt securities.
This makes it easier for investors to access a variety of assets, including stocks, commodities, alternative investments, and unconventional assets such as real estate, collectibles, and cryptocurrencies.
What sets AMCs apart is their agility and cost-effectiveness. They quickly convert investment strategies into tradable securities, bridging the gap between traditional and unconventional assets. Banks, securities firms, or special purpose vehicles issue certificates that can be traded on exchanges or placed privately.
Increasing longevity investments in Europe
These companies’ goal is to increase capital in the longevity space and create real products and services for consumers.
In other words, we need research that proves rejuvenation is possible along with enough investment to make the fruits of that labor available. Ultimately, the adoption of rejuvenation biotechnology will be driven by consumers such as the healthcare industry.
The new AMC is open to professional investors starting at CHF 10,000 (around 11,000 USD). This is a lowering of the barrier to entry, as joining their regular longevity co-investment fund costs CHF 500,000.
“At Maximon, we see this as an interesting opportunity as we received many inquiries from professional investors who are not able or willing to invest the minimum amount to invest into our existing longevity co-investment fund.” – Marc P. Bernegger, Founding Partner of Maximon.
Maximon hopes this initiative will help to democratize investments in longevity by making it more accessible to professional investors. While this is not accessible for US and UK residents for regulatory reasons, it may still interest investors in Switzerland and the EU.
There is a lot happening in the longevity investment space; if you want to find out more, check out the DeSci Recap.
